Several US FDA approved immune checkpoint inhibitors (ICI), including Ipilimumab (anti-CTLA4), Pembrolizumab and Nivolumab (anti-PD1/PD-L1) have impressive anti-tumor effect in a subset of tumors [10]. This evidence concerns the gene CD274 and neoplasm.